Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 5/20 | 0.44 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514845 | 1.00 | KDM4E (0.46) | KDM4EKMT2ACYP24A1CYP27A1CYP26A1 | |
| SCHEMBL4521693 | 0.92 | KDM4E (0.41) | KDM4EKMT2ACYP24A1CYP27A1CYP26A1 | |
| SCHEMBL4510847 | 0.88 | SMN1; SMN2 (0.52) | KDM4EKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4523991 | 0.87 | MTNR1B (0.47) | KDM4EKMT2ACYP24A1CYP27A1ALDH1A1 | |
| SCHEMBL4524149 | 0.87 | KDM4E (0.43) | KDM4EKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4526694 | 0.86 | KDM4E (0.44) | KDM4EKMT2ACYP26A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4513609 | 0.86 | KDM4E (0.42) | KDM4EKMT2ACYP24A1CYP27A1ALDH1A1 | |
| SCHEMBL4516442 | 0.85 | ALDH1A1 (0.41) | KDM4EKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4528181 | 0.84 | PRMT5 (0.38) | KDM4EKMT2ACYP24A1CYP27A1ALDH1A1 | |
| SCHEMBL4500555 | 0.84 | CTSD (0.46) | KDM4EKMT2ACYP26A1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | KDM4E 2703/4885KMT2A 2379/4885CYP24A1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.